Acurx Pharmaceuticals, Inc. ACXP
At closeNov 4, 2026, 6:35 AM EST
Pre-market · Nov 4, 6:35 AM ET
- YTD
- -59.04%
- 1 year
- -79.84%
- Market cap
- 5.58M
- EPS (ttm)
- -2.67
- Shares out
- 16.89M
- Forward P/E
- -0.56
- YTD return
- -59.04%
- 1-year return
- -79.84%
- Volume
- 203.84K
- Avg volume
- 118.93K
- Open
- 1.07
- Previous close
- 1.07
- Day's range
- 1.01 – 1.11
- 52-week range
- 1.01 – 7.54
- Beta
- -1.72
- Analysts
- Buy
- Price target
- 11.19 (+997.1%)
- Earnings date
- Aug 9, 2024
6M -1.11 (-52.11%)
Key statistics
- Enterprise value
- 23.69M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -5.96M
- Total cash
- 6.36M
- Total debt
- 0
- Return on equity
- -346.94%
- Short % of float
- 3.43%
- 50-day average
- 1.46
- 200-day average
- 2.00
Analyst view
Consensus: buy
- Target (low)
- 10.00
- Target (mean)
- 11.19
- Target (high)
- 12.00
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate -0.18.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.23 | -0.17 | +0.06 | +26.09% |
| Aug 9, 2024 | Jun 1, 2024 | -0.28 | -0.26 | +0.02 | +7.14% |
| Aug 9, 2024 | Jun 1, 2024 | -0.28 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -0.24 | -0.28 | -0.04 | -16.67% |
| May 14, 2024 | Mar 1, 2024 | -0.24 | — | — | — |
| Mar 15, 2024 | Dec 1, 2023 | -0.26 | -0.38 | -0.12 | -46.15% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Feb 28, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- acurxpharma.com
News
Your note
Sign in to keep a note on ACXP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DELUCCIA ROBERT J | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 2, 2024 | 964,782 |
| LUCI DAVID P | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 2, 2024 | 1,098,280 |
| SAILER CARL | Director | Conversion of Exercise of derivative security | Jan 18, 2024 | 117,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.13% | 529,349 | 463.18K | Sep 29, 2024 |
| Prospect Financial Services LLC | 1.75% | 295,075 | 258.19K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.87% | 146,500 | 128.19K | Sep 29, 2024 |
| LPL Financial LLC | 0.27% | 44,780 | 39.18K | Sep 29, 2024 |
| Morgan Stanley | 0.27% | 46,201 | 40.42K | Sep 29, 2024 |
| State Street Corporation | 0.26% | 43,466 | 38.03K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.27% | 383,812 | 335.83K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.86% | 145,537 | 127.34K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 77,312 | 67.65K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 24,876 | 21.77K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 20,030 | 17.53K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 18,296 | 16.01K | Oct 30, 2024 |